There may be therapeutic value to identifying FSHR expression in ovarian cancers as has been demonstrated in patient-derived tissues; Perales-Puchalt et al. suggest that FSHR-expressing T cells may have utility in immunotherapy regimes that increase T cell targeting to ovarian cancer cells [75], a strategy that may be valuable in extending the relapse-free interval in ovarian cancer. This evidence concerns the gene FSHR and ovarian cancer.